This is a routine IP milestone for an early-stage diagnostics company. With a $1M market cap, no revenue or financial updates were provided. Traders should watch for commercial adoption metrics of CyPath Lung (test volumes, reimbursement wins) rather than patent news as the primary catalyst for BIAF/BIAFW warrants.
Price Chart
Executive Summary
bioAffinity Technologies announced it received a notification of allowance from the Mexican Institute of Industrial Property for a patent application protecting its CyPath Lung flow cytometry-based lung cancer detection method in Mexico. This expands the company's international IP portfolio, which already includes patents in the US, EU, China, Japan, Australia, and Canada. No financial terms or revenue impact were disclosed.
Key Facts
- Received notification of allowance from the Mexican Institute of Industrial Property for a patent covering methods of predicting lung cancer likelihood using flow cytometry.
- Upon issuance, the patent will protect the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum for lung cancer detection.
- CyPath Lung showed 92% sensitivity, 87% specificity, 88% accuracy, and 99% negative predictive value in a published clinical trial.
- The company's global patent portfolio now includes protection in the US, EU, China, Japan, Australia, Canada, and Mexico.
- $1 million market cap; warrants (BIAFW) trade on Nasdaq.
Financial Impact
No financial figures disclosed; IP expansion is a non-financial event with potential long-term strategic value.
Risk Factors
- Pending patent applications may not result in issued patents as noted in forward-looking statements.
- CyPath Lung is marketed as a Laboratory Developed Test (LDT) and faces potential increased FDA oversight risk.
- Company has very small market cap ($1M) and no disclosed revenue figures in this filing.
- Commercialization success in domestic and international markets remains uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-025338 |
| Exhibit: ex99-1.htm | 0001493152-26-025338 |
| Document: 0001493152-26-025338-index-headers.html | 0001493152-26-025338 |
| Document: 0001493152-26-025338-index.html | 0001493152-26-025338 |
| Document: 0001493152-26-025338.txt | 0001493152-26-025338 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 2, 2026 20w ago | 8-K | $0.2950 $0.1300 | ▼ −55.93% | ▼ −54.37% | — |
May 27, 2026 21w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▲ +1.90% | — |
May 13, 2026 23w ago | EFFECT | $0.2950 $0.2950 | · 0.00% | ▲ +0.61% | — |
May 12, 2026 23w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▲ +1.73% | — |
May 8, 2026 24w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▼ −0.02% | — |
Apr 14, 2026 27w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▼ −6.30% | — |
Apr 7, 2026 28w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▼ −9.78% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers